ME Therapeutics Holdings Inc. (CSE:METX)
Canada · Delayed Price · Currency is CAD 4.000
0.00 (0.00%)
Aug 14, 2025, 4:00 PM EDT
ME Therapeutics Holdings Company Description
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology.
Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer.
The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.
ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
ME Therapeutics Holdings Inc.
| Country | Canada |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Salim Dhanji |
Contact Details
Address: 177 Robson Street Vancouver, British Columbia V6B 0N3 Canada | |
| Phone | 236-516-7714 |
| Website | metherapeutics.com |
Stock Details
| Ticker Symbol | METX |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | September - August |
| Reporting Currency | CAD |
| SIC Code | 8049 |
Key Executives
| Name | Position |
|---|---|
| Dr. Salim Zulifkar Dhanji Ph.D. | Chief Executive Officer and Director |
| Quinn Martin C.A., CPA | Chief Financial Officer |
| Jamil Kassam | Corporate Secretary |
| Karim F. Lalji M.S., MS, SM | Chief Business Officer |